How would you manage endocrine therapy in a male patient with gBRCA2 with a metachronous contralateral ER+ breast CA that occurred while on adjuvant tamoxifen for a different ER+ breast CA?

This is a tough situation. There is very limited data on the risk of CBC in men with gBRCA2 pathogenic variants and its impact on survival. In general, men with breast cancer suffer a worse prognosis compared to their female counterparts, although a large part of this may be driven by late stage at ...